Release issued 9th October 2002

Embil Pharmaceutical Co. Ltd. has announced today, the availability of results of two new clinical studies on Kortos® HC cream.

1-Efficacy, tolerability and safety of Kortos® HC Cream and Kortos® HC Suppository in benign anorectal diseases.

The study was carried out to evaluate the efficacy, tolerability and safety of Kortos® HC Cream and Kortos® HC Suppository in patients with internal and external hemorrhoids, anal fissure and pruritus ani (101 patients).

According to statistical evaluations and the global efficacy and safety evaluation by the investigating physician, Kortos® HC Cream, either administered alone or in combination with Kortos® HC Suppository, was found to be highly efficacious and very well tolerated with no clinically relevant systemic or local side/adverse effects.

2- Efficacy, tolerability and safety of Kortos® HC Cream in benign anorectal diseases.

This study was carried out to evaluate the efficacy, tolerability and safety of Kortos® HC Cream in patients with internal /external hemorrhoids and/or anal fissure (10 patients).

According to statistical evaluations and the global efficacy and safety evaluation by the investigating physician, Kortos® HC Cream was found to be highly efficacious and very well tolerated with no systemic or local side/adverse effects.

Both these studies prove the high efficacy and safety of this unique formulation, which is reflecting itself in the marketplace through increasing market share against competitive products.

Kortos® HC Cream contains hydrocortisone acetate 0.5% (low potency topical corticosteroid) which reduces itching, inflammation and discomfort by vasoconstriction, lysosomal membrane stabilization and antimitotic activity; benzocaine 2.5% (local anesthetic) which relieves pain, burning, itching, discomfort and irritation in the anorectal area by preventing the transmission of nerve impulses; bismuth subgallate, 2% (astringent) which coagulates the protein in skin cells, thereby protecting the underlying tissue and decreasing the cell volume. It also lessens mucus and other secretions and helps relieve local anorectal irritation and inflammation; benzalkonium chloride 0.1% (antiseptic) inhibits growth of microorganisms in the anorectal region.

Kortos® Cream contains Dimethicone, which protects the anorectal area against maceration and provides a longer lasting action by preventing loss (or leakage) of active substances from the application site by forming a hydrophobic layer between the skin and water.

(17th November 2004) Sulidin® 1% Nimesulide LPS® gel receives European and US Patents

(7th November 2004) New Clinical Study results on SULIDIN® 1% Nimesulide LPS gel presented at the 8'th World Congress on Clinical Pharamacology and Therapeutics, Brisbane, Australia, 1-6 August 2004.

(29th December 2003) Two papers on Neo-Penotran® Forte and Neo-Penotran® Forte-L have been accepted for presentation at the 4'th World Conference on Vaginitis, Costa Rica, 10-13 Jan 2004

(6th June 2003) Australian Patent Approval announced for SULIDIN LPS (Topical Nimesulide Gel) formulation.

(10th October 2002) Recent Patent Approvals for SULIDIN® LPS® (Topical Nimesulide Gel)